Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Athero-flux

Kennedy
Logo

Athero-Flux consortium consists of eleven partners from nine EU countries (UK, Denmark, Finland, Germany, Italy, Sweden, Greece, France and Israel)

OBJECTIVES

Athero-Flux aims to identify, characterise and validate novel therapeutic targets for CVD by dissecting the biosynthesis and pro-atherogenic potential of specific molecular species of SLs identified by lipidomics as strong predictors of CV risk in large-scale clinical studies.

 Specific objectives:

Objective 1: To identify the steps regulating the generation and signalling of specific SLs relevant to CV risk
Objective 2: To validate therapeutic targets in SL metabolism and downstream signalling using atherosclerosis models in vitro and in vivo
Objective 3: To develop clinically applicable LNA-based therapeutics for the treatment of CVD and its acute complications

Our team